Related Experiment Video

Updated: Aug 9, 2026

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the

S Lafarge1, V Sylvain, M Ferrara

  • 1Laboratoire d'Oncologie Moléculaire, Centre Jean Perrin, BP 392, 63011 Clermont-Ferrand cedex 1-France.

Oncogene
|October 20, 2001
PubMed

Insights

Inhibiting BRCA1 expression with ribozymes (Rz) altered breast cancer cell sensitivity to chemotherapy. BRCA1 suppression impacted the JNK pathway, affecting responses to microtubule-interfering agents.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Biochemistry

Background:

  • BRCA1 gene plays a crucial role in DNA repair and cellular response to stress.
  • Understanding BRCA1's function in chemosensitivity is vital for developing targeted cancer therapies.

Purpose of the Study:

  • To investigate the role of BRCA1 in chemosensitivity using ribozymes (Rz) to inhibit its expression.
  • To elucidate the molecular mechanisms underlying BRCA1's influence on cellular response to chemotherapy, particularly the JNK pathway.

Main Methods:

  • Development and delivery of two ribozymes (Rz) targeting BRCA1 mRNA in HBL100 breast cancer cells via retroviral vectors.
  • Quantification of BRCA1 expression using real-time PCR and Western blotting.
  • Assessment of cellular sensitivity to various chemotherapeutic agents (cisplatin, etoposide, taxol, vincristine) and analysis of the JNK signaling pathway.

Main Results:

  • Achieved 79-99% inhibition of BRCA1 expression in Rz-treated cells.
  • BRCA1 inhibition resulted in sensitivity to DNA damaging agents but resistance to microtubule-interfering agents (MIA).
  • BRCA1 suppression altered JNK pathway gene expression and phosphorylation of c-jun, indicating pathway modulation.

Conclusions:

  • The BRCA1-JNK pathway is integral to the cytotoxic response to MIA treatment.
  • Inhibition of BRCA1 expression leads to significant transcriptional modifications within the JNK pathway.
  • Targeting BRCA1 offers a potential strategy to modulate chemosensitivity in cancer treatment.

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...